Copyright: Press Eye Photography
Alastair Hamilton, Invest NI and Dr Claire Gilligan, Warner Chilcott watch as Cathy Coulter of Warner Chilcott (left) demonstrates some of the activities being carried out at the company¹s Larne facility as part of a £6.6m R&D investment supported by Invest NI and the EU.
Invest NI Chief Executive Alastair Hamilton has announced that Warner Chilcott UK Limited, a subsidiary of the Irish pharmaceutical company Warner Chilcott plc (NASDAQ: WCRX), has commenced a £6.6 million development project at its Larne research and development facility.
Warner Chilcott plc is a leading specialty pharmaceutical company currently focused on the gastroenterology, women’s healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.
The £6.6 million investment will enhance Warner Chilcott’s technical knowledge and capabilities, specifically in the development of a new drug delivery system. Invest NI has offered £1.65 million of support towards the project which includes part funding from the European Regional Development Fund (ERDF).
Mr. Hamilton made the announcement during the opening of a new research and development area at Warner Chilcott’s Larne site which was constructed specifically to house new product development activities.
“The pharmaceutical industry is particularly competitive with new drugs and methods of delivery continually being brought to market,” said Mr Hamilton. “A focused R&D strategy is essential if a strong pipeline of commercially viable new products is to be maintained. This is equally important for all companies, across all sectors. Warner Chilcott is a key player in the local life sciences sector and its reputation for innovation, combined with world class skills has already
delivered success in global markets. This project will ensure that research into new products continues to be carried out at the Larne facility and that its research capabilities are further enhanced.”
Dr Claire Gilligan, Vice President, UK Operations, at Warner Chilcott commented: “For many years Warner Chilcott has focused on the development of innovative dosage systems, particularly in the female health care market. With dosage forms becoming increasingly complex and the approval of products becoming increasingly challenging, we believe that continuous investment in R&D will be essential to our efforts to remain competitive. With the assistance of Invest NI we look forward to expanding our existing research and development capabilities at our Larne facility and continuing our efforts to bring the next generation of innovative pharmaceutical products to the marketplace.”